Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Durvalumab/德瓦鲁单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
HUVECs
4 μmol/L
6 hours
To evaluate the effect of Durvalumab on angiogenesis, results showed that Durvalumab significantly inhibited tube formation in HUVECs.
Cancer Commun (Lond). 2021 Jun;41(6):511-527
HeyA8 cells
4 μmol/L
48 hours
To evaluate the effect of Durvalumab on ovarian cancer cell migration and invasion, results showed that Durvalumab significantly inhibited cell migration and invasion.
Cancer Commun (Lond). 2021 Jun;41(6):511-527
OVCA433 cells
4 μmol/L
48 hours
To evaluate the effect of Durvalumab on ovarian cancer cell migration and invasion, results showed that Durvalumab significantly inhibited cell migration and invasion.
Cancer Commun (Lond). 2021 Jun;41(6):511-527
Jurkat.PD1-NFAT-luc cells
0.01–10 mg/ml
18 hours
To evaluate the blocking capacity of PD-L1xEGFR on PD-1/PD-L1 interaction. Results showed PD-L1xEGFR regained potent PD-L1-blocking activity comparable to MEDI4736 in EGFR-directed setting.
Oncoimmunology. 2018 May 31;7(8):e1466016
FaDu cells
5 µg/ml
3 days
To evaluate the enhancement of cytotoxic activity of BIS-1-redirected T cells by PD-L1xEGFR. Results showed PD-L1xEGFR significantly increased apoptotic cancer cell death.
Oncoimmunology. 2018 May 31;7(8):e1466016
A431 cells
5 µg/ml
3 days
To evaluate the enhancement of cytotoxic activity of BIS-1-redirected T cells by PD-L1xEGFR. Results showed PD-L1xEGFR significantly increased apoptotic cancer cell death.
Oncoimmunology. 2018 May 31;7(8):e1466016
MDA MB-231 human breast cancer cells
51 ± 15 pM
Measure the binding affinity of Durvalumab to PD-L1 on MDA MB-231 cells
MAbs. 2021 Jan-Dec;13(1):1857100
Jurkat T cells
10 ± 5.7 pM
Measure the binding affinity of Durvalumab to PD-L1 on Jurkat T cells
MAbs. 2021 Jan-Dec;13(1):1857100
Durvalumab/德瓦鲁单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mouse
Kras-driven NSCLC models
Intraperitoneal
5 mg/kg (anti-PD-1) and 10 mg/kg (anti-CTLA4)
Twice weekly for 2 weeks
Validate efficacy of dual immune checkpoint blockade (anti-PD-1 + anti-CTLA4) in STK11/KEAP1-deficient models
Nature. 2024 Nov;635(8038):462-471
NSG mice
MDAMB231 xenograft model
Intravenous injection
1 mg/kg
Single dose at 24 or 96 hours
To evaluate PD-L1 occupancy by Durvalumab in tumors
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2107982118
Mouse
CT26, MC38, 4T1, A20 tumor models
Oral
10 mg/kg b.i.d.
7 days-on/7 days-off, every 28 days
Assessed the antitumor efficacy of ceralasertib combined with durvalumab, showing CD8+T-cell dependent antitumor activity and modulation of the tumor immune microenvironment
Nat Commun. 2024 Feb 24;15(1):1700
Mice
MC38-OVA tumor model
Intraperitoneal
10 mg/kg
Twice weekly for 14 days
To evaluate the antitumor efficacy of Durvalumab in combination with AZD4635, showing significant reduction in tumor volume and enhanced CD103+ DC function and T cell response.
J Immunother Cancer. 2020 Jul;8(2):e000417
Mice
CT26 colon cancer model
Intravenous injection
10 mg/kg
Single dose
Evaluate the pharmacokinetic properties of Durvalumab in mouse models
MAbs. 2021 Jan-Dec;13(1):1857100
NOG/SCID mice
Patient-derived xenograft model (PDX)
Tail vein injection
118.0 mg/kg
Two doses, 4 weeks apart
To evaluate the therapeutic effect of Durvalumab on high-PD-L1 expressing, GATA3/CR5/6-negative non-muscle invasive bladder cancer. Results showed that Durvalumab significantly prolonged survival time and tumor-doubling time in high-grade tumor-bearing mice and inhibited metastatic activity.
Int J Mol Sci. 2021 Sep 12;22(18):9856
NRG mice
Humanized NRG mouse model
Oral
10 mg/kg
Twice a week for 4 weeks
To evaluate the antitumor effects of Durvalumab in combination with BRAF and MEK inhibitors. Results showed that the triple combination group had the most significant reduction in tumor growth, along with increased expression of PD-L1 and CD8α, and higher degree of tumor necrosis.
Cancer Immunol Immunother. 2025 Mar 19;74(5):154
Durvalumab/德瓦鲁单抗 技术信息
CAS号
1428935-60-7
分子量
146.32 kDa
SMILES Code
NONE
MDL No.
N/A
别名
Durvalumab单抗
;MEDI 4736; Durvalumab(anti-PD-L1); MEDI 4736(anti-PD-L1)
搜索
